ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ruxolitinib

Also written as “Ruxolitinib”, “Ruxolitinib cream” and “Ruxolitinib Cream”.

Its studies are mostly in Primary Myelofibrosis · Dermatitis, Atopic · Vitiligo · Graft vs Host Disease · Pancreatic Neoplasms, led by 3 companies.

Drug pageRuxolitinib: every studyAll 302 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 13, 202390 company-led studies, 14 open or runningNext primary completion: Dec 9, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte689 open or runningphase 4since Jan 13, 2023Jul 30, 2007Dec 9, 2026phase 1 · NCT07049575
Novartisits history only214 open or runningphase 4since Mar 16, 2012Jul 6, 2009May 10, 2029phase 4 · NCT06824103
Suzhou Junjing BioSciencesits history only11 open or runningphase 2since Mar 27, 2025Mar 27, 2025Oct 31, 2027phase 2 · NCT06909136

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Incyte only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Aug 4, 2009.

  1. Mar 1, 2023Phase 3 study in PrurigoNCT05764161 · 190 enrolled · United States, Australia, Austria and more
  2. Jun 7, 2023Phase 2 study in EczemaNCT05906628 · 186 enrolled · United States, Canada, Germany and more
  3. Jan 10, 2024Phase 1 study in Prurigo NodularisNCT06213831 · 23 enrolled · United States
  4. Jan 25, 2024Phase 3 study in Dermatitis, AtopicNCT06238817 · 241 enrolled · United States, Australia, Belgium and more
  5. Mar 7, 2024Phase 1 study in Healthy ParticipantsNCT06310304 · 24 enrolled · United States
  6. Apr 25, 2024Phase 2 study in Bronchiolitis Obliterans SyndromeNCT06388564 · 130 enrolled · United States, Belgium, Canada and more
  7. Aug 8, 2024Phase 3 study in NonSegmental VitiligoNCT06548360 · 180 planned · United States, Canada
  8. Aug 12, 2024Phase 1 study in Healthy ParticipantsNCT06555081 · 168 enrolled · United States
  9. Sep 6, 2024Phase 3 study in Graft vs Host DiseaseNCT06615050 · 572 planned · United States
  10. Jan 27, 2025Phase 3 study in NonSegmental VitiligoNCT06804811 · 250 planned · Argentina, Austria, Belgium and more
  11. Feb 4, 2025Phase 3 study in Dermatitis, AtopicNCT06832618 · 159 enrolled · United States, Belgium, Canada and more
  12. Apr 25, 20252 phase 3 studies in Hidradenitis SuppurativaNCT06958211, NCT06959225
  13. Jun 25, 2025Phase 1 study in Hidradenitis SuppurativaNCT07049575 · 24 planned · United States
  14. May 8, 2026Phase 1 study in Healthy ParticipantsNCT07588139 · 24 enrolled · United States

Ahead

  1. Dec 9, 2026Primary completion: phase 1 study in Hidradenitis SuppurativaNCT07049575
  2. Apr 30, 2027Primary completion: phase 3 study in NonSegmental VitiligoNCT06804811
  3. Sep 30, 2027Primary completion: phase 2 study in Pancreatic NeoplasmsNCT02955940
  4. Jun 5, 2028Primary completion: phase 3 study in NonSegmental VitiligoNCT06548360

TargetBeta

“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
delgocitinibruleLEO Pharmaphase 321

Studies

The newest 60 of 68 Incyte leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07588139Healthy Participants · United States1CompletedSep 8, 202624
NCT07049575Hidradenitis Suppurativa · United States1RecruitingDec 9, 202624
NCT06959225Hidradenitis Suppurativa · United States, Bulgaria, Canada and more3Active, not recruitingOct 29, 2026580
NCT06958211Hidradenitis Suppurativa · United States, Belgium, Bulgaria and more3Active, not recruitingOct 1, 2026573
NCT06832618Dermatitis, Atopic · United States, Belgium, Canada and more3Active, not recruitingAug 7, 2026159
NCT06804811NonSegmental Vitiligo · Argentina, Austria, Belgium and more3RecruitingApr 30, 2027250
NCT06615050Graft vs Host Disease · United States3RecruitingJan 17, 2031572
NCT06555081Healthy Participants · United States1CompletedOct 25, 2024168
NCT06548360NonSegmental Vitiligo · United States, Canada3RecruitingJun 5, 2028180
NCT06388564Bronchiolitis Obliterans Syndrome · United States, Belgium, Canada and more2Active, not recruitingOct 1, 2026130
NCT06310304Healthy Participants · United States1CompletedApr 16, 202424
NCT06238817Dermatitis, Atopic · United States, Australia, Belgium and more3CompletedMay 21, 2025241
NCT06213831Prurigo Nodularis · United States1CompletedJul 17, 202523
NCT05906628Eczema · United States, Canada, Germany and more2CompletedJul 15, 2024186
NCT05764161Prurigo · United States, Australia, Austria and more3CompletedDec 30, 2024190
NCT05750823Vitiligo · United States, Canada, France2CompletedMar 6, 202549
NCT05755438Prurigo · United States, Argentina, Belgium and more3CompletedOct 7, 2024204
NCT05696392Dermatitis, Atopic · United States4TerminatedJan 22, 202547
NCT05635838Hidradenitis Suppurativa · United States, Canada2CompletedOct 19, 202369
NCT05593445Lichen Sclerosus et Atrophicus · United States, Canada2CompletedSep 1, 202361
NCT05593432Lichen Planus · United States, Canada2CompletedOct 2, 202364
NCT05456529Dermatitis, Atopic · United States, Canada, Poland3CompletedMay 17, 2024103
NCT05247489Vitiligo · United States, Canada2CompletedDec 19, 202355
NCT05233410Eczema · United States, Bulgaria, Canada and more3WithdrawnApr 25, 20240
NCT05219864Eczema · United States, Canada, Czechia and more3WithdrawnApr 25, 20240
NCT05127421Dermatitis, Atopic · United States2CompletedAug 3, 202377
NCT05034822Dermatitis, Atopic · United States1CompletedAug 7, 202329
NCT04921969Dermatitis, Atopic · United States, Canada3CompletedMay 10, 2023330
NCT04896385Vitiligo · United States, Canada, France2CompletedNov 17, 202260
NCT04839380Dermatitis, Atopic · Canada2CompletedNov 18, 202249
NCT04530344Vitiligo · United States, Bulgaria, Canada and more3CompletedNov 14, 2022458
NCT04377620COVID-19 · United States, Russian Federation3TerminatedFeb 26, 2021211
NCT04057573Vitiligo · United States, Bulgaria, Canada and more3CompletedMar 15, 2021344
NCT04052425Vitiligo · United States, Bulgaria, Canada and more3CompletedMar 18, 2021330
NCT03920852Dermatitis, Atopic · United States, Canada1CompletedDec 26, 201941
NCT03745651Dermatitis, Atopic · United States, Bulgaria, Canada and more3CompletedNov 18, 2019618
NCT03745638Dermatitis, Atopic · United States, Canada, France and more3CompletedDec 23, 2019631
NCT03257644Dermatitis, Atopic · United States1CompletedOct 7, 202070
NCT03123588Myeloproliferative Disorders · United States2TerminatedAug 3, 202012
NCT03112603Graft vs Host Disease · United States, Australia, Austria and more3CompletedMay 8, 2020330
NCT03099304Vitiligo · United States2CompletedSep 12, 2018157
NCT03011892Dermatitis, Atopic · United States, Canada2CompletedJan 10, 2018307
NCT02955940Pancreatic Neoplasms · United States, Poland2Active, not recruitingSep 30, 202710
NCT02953678Graft vs Host Disease · United States2CompletedJan 31, 201871
NCT02723994Leukemia · United States, Canada, Puerto Rico2CompletedMar 3, 2026171
NCT02553330Alopecia Areata · United States2TerminatedOct 3, 201790
NCT02120417Breast Neoplasms · United States, France, Italy and more2TerminatedFeb 2016149
NCT02119676Colorectal Neoplasms · United States, Australia, France and more2TerminatedFeb 2016396
NCT02119663Pancreatic Neoplasms · United States, Austria, Chile and more3TerminatedFeb 201686
NCT02119650Carcinoma, Non-Small-Cell Lung · United States2TerminatedFeb 11, 201676
NCT02117479Pancreatic Neoplasms · United States, Australia, Belgium and more3TerminatedFeb 2016321
NCT01822756Pancreatic Neoplasms · United States1TerminatedSep 201542
NCT01632904Polycythemia Vera · United States, Belgium, Germany and more3CompletedMar 2014110
NCT01445769Primary Myelofibrosis · United States2CompletedMar 201345
NCT01423604Pancreatic Neoplasms · United States2CompletedJun 2013136
NCT01348490Myeloproliferative Disorders · United States2CompletedDec 19, 201866
NCT01340651Primary Myelofibrosis · United States2CompletedJul 201241
NCT01317875Primary Myelofibrosis · United States, Austria, China and more1CompletedDec 31, 201969
NCT01243944Polycythemia Vera · United States, Argentina, Australia and more3CompletedJan 15, 2014222
NCT00952289Myeloproliferative Disorders · United States, Australia, Canada3CompletedNov 2010309

How it is read

Names in the registry

  • “Ruxolitinib”, 44 entries
  • “Ruxolitinib cream”, 14 entries
  • “Ruxolitinib Cream”, 11 entries
  • “ruxolitinib”, 6 entries
  • “Ruxolitinib phosphate cream”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.